Carnosine: A Possible Drug for Vascular Dementia
Dai Mizuno* and Masahiro Kawahara
Department of Bio Analytical Chemistry, Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan
- *Corresponding Author:
- Dai Mizuno
Department of Bio Analytical Chemistry
Research Institute of Pharmaceutical Sciences
Musashino University, Nishitokyo-shi
Tokyo, 202-8585, Japan
E-mail: [email protected]
Received Date: July 16, 2014; Accepted Date: December Aug 11, 2014; Published Date: August 13, 2014
Citation: Mizuno D, Kawahara M (2014) Carnosine: A Possible Drug for Vascular Dementia. J Vasc Med Surg 2:146. doi: 10.4172/2329-6925.1000146
Copyright: © 2014 Dai Mizuno, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Carnosine (β–alanyl histidine) is a small dipeptide with numerous beneficial effects, including the maintenance of the acid–base balance, antioxidant, chelating, anti–crosslinking, and anti–glycation activities in the living organism. High levels of carnosine are found in the skeletal muscles and in the brain. We have found that carnosine inhibits Zn2+–induced neuronal death, which plays acrucial role in the pathogenesis of vascular dementia. Our previous research demonstrated that carnosine participates in the Endoplasmic Reticulum (ER)–stress pathway in Zn– induced neurotoxicity and we have applied for a patent related to drugs for Vascular Dementia (VD). Here, we review the roles of carnosine in VD and otherneuro degenerative diseases and discuss perspectives about the future therapeutic use ofthis dipeptide.